Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Juli 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.1k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • B Offline
    B Offline
    bibob
    wrote on sidst redigeret af
    #966

    Tisotumab shows favorable activity in Ovarian cancer. https://www.onclive.com/view/tisotumab-vedotin-shows-favorable-activity-in-recurrent-or-metastatic-cervical-cancer?eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==

    1 Reply Last reply
    0
    • S Offline
      S Offline
      Sukkeralf
      wrote on sidst redigeret af
      #967

      Cervical cancer

      1 Reply Last reply
      0
      • M Offline
        M Offline
        Mogan
        wrote on sidst redigeret af
        #968

        God morgen 😉

        1 Reply Last reply
        0
        • Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktør
          wrote on sidst redigeret af
          #969

          Tak bibob.

          1 Reply Last reply
          0
          • B Offline
            B Offline
            bibob
            wrote on sidst redigeret af
            #970

            Tak Sukker. Selvfølgelig. 😉

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #971

              Phase 3 Amivantamab trial,
              1000 participants!!

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #972

                A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) https://www.clinicaltrials.gov/ct2/show/NCT04487080?recrs=ab&cond=Lung+Cancer&sfpd_s=07%2F14%2F2020&sfpd_d=14&sel_rss=new14

                1 Reply Last reply
                0
                • M Offline
                  M Offline
                  Mcjean
                  wrote on sidst redigeret af
                  #973

                  Wouw thats a lot, isnt it?

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #974

                    Yes it is. They perhaps need power to show better effect. What do Osimertinib have in revenue ?

                    1 Reply Last reply
                    0
                    • SolsenS Offline
                      SolsenS Offline
                      Solsen
                      wrote on sidst redigeret af
                      #975

                      Tagrisso: $982M (+56%) Q120

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #976

                        Novartis also with a new trial , for patients that want to switch to Ofa from another CD20 https://www.clinicaltrials.gov/ct2/show/NCT04486716?term=NCT04486716&draw=2&rank=1

                        1 Reply Last reply
                        0
                        • SolsenS Offline
                          SolsenS Offline
                          Solsen
                          wrote on sidst redigeret af
                          #977

                          Lidt mere om Lazertinib https://www.fiercebiotech.com/biotech/janssen-taps-south-korea-s-yuhan-for-tagrisso-rival Gode data og baren er sat højt.

                          1 Reply Last reply
                          0
                          • SolsenS Offline
                            SolsenS Offline
                            Solsen
                            wrote on sidst redigeret af
                            #978

                            Barren skulle der stå 😉

                            1 Reply Last reply
                            0
                            • J Offline
                              J Offline
                              Joakim_Von_And
                              wrote on sidst redigeret af
                              #979

                              De stoffer I nævner Amivantamab, Lazertinib..Hvem har de forbindelse til ? Kan ikke finde ud af om det er godt eller skidt for genmab.

                              1 Reply Last reply
                              0
                              • G Offline
                                G Offline
                                gentogen
                                wrote on sidst redigeret af
                                #980

                                Amivantamab (JNJ-61186372) is a bispecific antibody that targets EGFR and cMet, two validated cancer targets. The two antibodies used to create amivantamab (JNJ-61186372) were both created by Genmab.

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #981

                                  God morgen. 🙂

                                  1 Reply Last reply
                                  0
                                  • B Offline
                                    B Offline
                                    bibob
                                    wrote on sidst redigeret af
                                    #982

                                    God morgen. 🙂

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #983

                                      Der må falde en milestone når fase III med amivantamab starter op - ligeledes når første registreringsansøgning indsendes sidt på året. Bliver spændende at se hvor backloaded disse aftaler er

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #984

                                        Nogen der husker strukturen på en lignende aftale. Den er selvfølgelig backloaded i høj grad, men må også være ret simpel, da man jo for mange af programmerne ikke kendte targets og dermed mulige indikationer. Så mon den alene går på første indikation der kommer hele vejen, for de milestones det gælder klinisk udvikling og registrering. Gætter på at mindst halvdelen af milestonepakken er salgsmilestones

                                        1 Reply Last reply
                                        0
                                        • B Offline
                                          B Offline
                                          BioShare
                                          wrote on sidst redigeret af
                                          #985

                                          Gik alt, alt for langsomt med at få indrullet patienterne i det ACCORD-studie....trist. I stedet startes et nye forsøg op "overseas"...

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger